INT135443

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 2.44
Pain Relevance 8.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Map2k1) Golgi apparatus (Map2k1) cytoplasm (Map2k1)
cell proliferation (Map2k1) cytosol (Map2k1) mitosis (Map2k1)
Anatomy Link Frequency
brain 3
striatum 2
neurons 1
cerebral cortex 1
nucleus 1
Map2k1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cerebral cortex 6 99.68 Very High Very High Very High
withdrawal 31 99.60 Very High Very High Very High
Opioid 38 99.38 Very High Very High Very High
Morphine 38 99.34 Very High Very High Very High
narcan 12 98.58 Very High Very High Very High
agonist 25 98.24 Very High Very High Very High
Kappa opioid receptor 18 98.06 Very High Very High Very High
opioid receptor 6 94.56 High High
intrathecal 17 87.36 High High
addiction 13 81.84 Quite High
Disease Link Frequency Relevance Heat
Opiate Addiction 30 99.60 Very High Very High Very High
Apoptosis 9 98.32 Very High Very High Very High
Stress 25 86.36 High High
Death 10 78.12 Quite High
Cv Unclassified Under Development 6 74.56 Quite High
Middle Cerebral Artery Infarction 27 69.32 Quite High
Pain 51 50.00 Quite Low
Bacillus Anthracis Infection 28 50.00 Quite Low
Brain Hemorrhage 5 50.00 Quite Low
Injury 15 16.48 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fig. 8 indicated that neither lethal toxin (5 nM, 2 hrs) nor apocynin (100 nM) or both significantly altered the phosphorylation of MEK1/2, p38 MAP kinase, ERK and JNK.
Phosphorylation (phosphorylation) of MEK1
1) Confidence 0.80 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2954163 Disease Relevance 0.59 Pain Relevance 0
The MEK1/2 inhibitor PD98059 was used as the inhibitor for ERK phosphorylation.
Phosphorylation (phosphorylation) of MEK1
2) Confidence 0.79 Published 2008 Journal Mol Pain Section Body Doc Link PMC2661045 Disease Relevance 0 Pain Relevance 0.14
Morphine (100 mg/kg, 2 h) also augmented MEK1/2 phosphorylation in the both brain regions (50-70%).
Phosphorylation (phosphorylation) of MEK1 in brain associated with morphine
3) Confidence 0.79 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.23 Pain Relevance 1.30
In morphine-dependent rats, however, naloxone (2 mg/kg)-precipitated withdrawal (2-6 h) induced robust increases in MEK1/2 phosphorylation in cortex (27-49%) and striatum (83-123%).
Phosphorylation (phosphorylation) of MEK1 in striatum associated with narcan, withdrawal and morphine
4) Confidence 0.79 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.23 Pain Relevance 1.46
Chronic morphine (10-100 mg/kg, 5 days) was not associated with alterations in the content of phosphorylated MEK1/2 in the brain (induction of tachyphylaxis to the acute effects).
Phosphorylation (phosphorylated) of MEK1 in brain associated with morphine
5) Confidence 0.79 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.27 Pain Relevance 1.54
This study was designed to assess the acute effects of selective mu-, delta-, and kappa-opioid receptor agonists, as well as those induced by chronic morphine and opioid withdrawal, on the content of phosphorylated MEK1/2 in the rat brain.
Phosphorylation (phosphorylated) of MEK1 in brain associated with agonist, kappa opioid receptor, withdrawal, opioid and morphine
6) Confidence 0.79 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.26 Pain Relevance 1.12
Sufentanil (1-30 microg/kg, 30-120 min) induced dose- and time-dependent increases in MEK1/2 phosphorylation in the cerebral cortex and corpus striatum (30-177%) through a naloxone-sensitive mechanism.
Phosphorylation (phosphorylation) of MEK1 in cerebral cortex associated with narcan and cerebral cortex
7) Confidence 0.79 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.25 Pain Relevance 1.19
Sufentanil (1-30 microg/kg, 30-120 min) induced dose- and time-dependent increases in MEK1/2 phosphorylation in the cerebral cortex and corpus striatum (30-177%) through a naloxone-sensitive mechanism.
Phosphorylation (phosphorylation) of MEK1 in corpus striatum associated with narcan and cerebral cortex
8) Confidence 0.27 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16678156 Disease Relevance 0.25 Pain Relevance 1.19
In addition, U0126 increases phosphorylation of MEK1/2 in cortical neurons; hence, U0126 does not affect upstream components of MEK1/2 [19].
Phosphorylation (phosphorylation) of MEK1 in neurons
9) Confidence 0.19 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2553085 Disease Relevance 0.35 Pain Relevance 0.07
Interruption of ERK signalling may occur by (1) hyperphosphorylation of Raf and MEK 1 and 2, (2) dephosphorylation of aminoacidic residues of ERK and (3) sequestration of ERK in the nucleus.
Phosphorylation (dephosphorylation) of MEK 1 in nucleus
10) Confidence 0.15 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644492 Disease Relevance 0 Pain Relevance 0
Raf, from which 3 isoforms are known, is the first to become active and phosphorylates MEK 1 and 2 at two serine or threonine residues.
Phosphorylation (phosphorylates) of MEK 1
11) Confidence 0.15 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644492 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox